Concepedia

Kathy Tolzien

KT

Statistics

Publications

7

Citations

192

H-Index

7

Active since

2009

Affiliations

Advocate Lutheran General Hospital(Current)

Oncology Specialists

University of Chicago

Kathy Tolzien is an author at Advocate Lutheran General Hospital specializing in oncology, cancer pharmacology, and prostate cancer.

Publications per year

2009–2013

7

Publications

7

A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naïve castration-resistant prostate cancer

Kimberly Kruczek, Megan Ratterman, Kathy Tolzien et al. · British Journal of Cancer · 2013 · 56 citations · Full text

Medicine, Oncology, Pharmacology +17

Erlotinib Has Moderate Single-agent Activity in Chemotherapy-naïve Castration-resistant Prostate Cancer: Final Results of a Phase II Trial

Chadi Nabhan, Timothy M. Lestingi, Ángel Gálvez et al. · Urology · 2009 · 54 citations

Medicine, Oncology, Urology +14

Lenalidomide Monotherapy in Chemotherapy-Naive, Castration-Resistant Prostate Cancer Patients: Final Results of a Phase II Study

Chadi Nabhan, Anand Patel, Dana Villines et al. · Clinical Genitourinary Cancer · 2013 · 21 citations · Full text

Medicine, Oncology, Pharmacology +15

Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer

Chadi Nabhan, Dana Villines, Tina V. Valdez et al. · British Journal of Cancer · 2012 · 18 citations · Full text

Pharmacy, Oncology, Pharmacology +16

Efficacy and safety of clofarabine in relapsed and/or refractory non‐hodgkin lymphoma, including rituximab‐refractory patients

Chadi Nabhan, Nancy Davis, Jacob D. Bitran et al. · Cancer · 2010 · 17 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +15

1–5 of 7